National News

Changes to the way you access the Drug Tariff

PSNC News - 20 November 2018 - 4:31pm

NHS England has announced that it will stop automatically sending monthly hard copies of the Drug Tariff out to community pharmacies after the January 2019 edition.

As part of NHS England’s sustainable development strategy and commitment to make services available online where possible, community pharmacy contractors will only receive the printed copy of the Drug Tariff if they have requested to do so.

Pharmacy teams are being encouraged to make use of the online versions of the Drug Tariff which can be accessed on the NHS Business Services Authority website. Also, PSNC publishes a monthly ‘Drug Tariff Watch’ article in CPN magazine and on our website which can help contractors prepare for upcoming changes.

To continue receiving the monthly hard copy email a request to DTBsurvey@nhs.net by 10th January 2019. In your email please state that you wish to opt-in to receive the monthly hard copy Drug Tariff from 2019 and provide:

  • Your name
  • Your business name and address
  • F-code/ODS code*
  • Any days you are not open and alternative delivery instructions for those days

*This code appears at the top of your monthly FP34 Schedule of Payments.

Any pharmacies that chose not to opt-in will still receive one paper Drug Tariff each year (in January).

Primary Care Support England (PCSE) will be distributing a flyer containing information about this change to all pharmacy branches along with the hard copy of the December Drug Tariff. Any queries should be directed to pcse.enquiries@nhs.net

Categories: National News

Flu vaccine ordering for 2019/20

PSNC News - 20 November 2018 - 4:01pm

Public Health England (PHE) has today (20th November 2018) issued a joint letter with NHS England and the Department of Health and Social Care to provide guidance to pharmacy contractors and general practices on ordering flu vaccines for the 2019/20 season.

This follows a review of the latest evidence on influenza vaccines conducted by the Joint Committee on Vaccination and Immunisation (JCVI), the body that advises UK health departments on immunisation, and the issuing of advice on the most effective vaccines for the 2019/20 flu season.

The joint letter advises that both of the vaccines that were recommended for the 2018/19 season (quadrivalent inactivated vaccine and adjuvanted trivalent inactivated vaccine) will continue to be recommended for next year. Both vaccines are currently licensed and available to order for use in the UK.

As in the 2018/19 season, standard trivalent vaccines (TIVe, previously known as TIV) are not to be used in any age or clinical at-risk group.

PHE also anticipate that two further products will be licensed within the ordering window for the 2019/20 flu season: a cell-based QIV, which will be suitable for use both in those aged 18 to 64 years and in those aged 65 years and over; and a high dose trivalent vaccine (TIV-HD) which will be suitable for those aged 65 years and over. Once licences are granted and list prices of the new vaccines have been agreed, NHS England will write to pharmacies and general practices confirming the full recommendations for the 2019/20 flu programme.

What should you do now?

Read the joint letter and begin ordering currently licensed vaccines as set out in the letter; ordering of these licensed vaccines should not be unnecessarily delayed.

For the new, currently unlicensed vaccines, please wait for confirmation from NHS England that they are eligible for reimbursement before ordering.

 

Categories: National News

Pharmacy technicians survey: Share your views on supervision

PSNC News - 20 November 2018 - 11:01am

The Association of Pharmacy Technicians UK (APTUK) has launched a survey to gather views on supervision from pharmacy technicians.

The APTUK Rebalancing Task and Finish group are seeking the opinions of pharmacy technicians and pre-registration trainee pharmacy technicians so that they are able to confidently represent the views of the pharmacy technician profession, nationally. Your anonymised responses will be analysed and collated to produce a survey report and will inform the future APTUK position on supervision. This will subsequently be used in future debates and discussions on this topic both within the pharmacy profession and at government level.

To help respondents to formulate informed answers APTUK has provided background information along with its current supervision position statements on the APTUK website: www.aptuk.org/supervision

The survey closing date is midnight 14th December 2018 and can be found here: Supervision: Identifying the Pharmacy Technician perspective

Categories: National News

Quality Payments: Support for meeting the asthma quality criterion

PSNC News - 19 November 2018 - 3:25pm

Support is now available from PSNC and on PharmOutcomes to assist community pharmacy contractors with meeting the asthma quality criterion of the Quality Payments Scheme.

Contractors who plan to claim for this quality criterion are required, on the day of the review (15th February 2019), to show evidence of patients with asthma, for whom more than six short-acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a six month period, have since 29th June 2018 (i.e. the last review date) been referred to an appropriate healthcare professional for an asthma review. For this review point, contractors are also required to evidence that they have ensured that all children aged 5-15 years prescribed an inhaled corticosteroid for asthma have a spacer device, where appropriate, in line with the National Institute for Health and Care Excellence’s Technology Appraisal guidance 38 and have a personalised asthma action plan (PAAP). Referral to an appropriate healthcare professional should be made where this is not the case.

PSNC has published Briefing 060/18: Quality Payments – Referrals for asthma review, which provides background information on the asthma quality criterion as well as the following template resources:

  • Suggested processes for identifying suitable patients – For pharmacy teams to consider following or adapting to incorporate this quality criterion into their daily practice;
  • Briefing document for GP practices – Can be used by contractors to talk local GP practices through the referral process;
  • Letter to GP practices – Can be used in addition to the above GP Briefing document;
  • GP notification form – Can be used to refer a patient to their GP practice to advise that the patient may need their asthma management to be reviewed; and
  • Data collection form – Contractors may be required to provide evidence to NHS England to show that they have met the quality criterion; this form could be used to aid this process.

These resources are all available as standalone documents at: psnc.org.uk/asthmareferrals

PharmOutcomes support

Contractors can also access support on PharmOutcomes for this quality criterion. This support has been made available to all contractors, as PSNC has agreed to use their licence to provide access to the two asthma referral services on PharmOutcomes.

There are two services available; one for patients for whom more than six short-acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a six month period and one for children who have not been prescribed a spacer device and/or a PAAP. These can be accessing by logging into PharmOutcomes, selecting ‘Services’; and then ‘Quality Payment criterion – Asthma referrals’ and ‘Quality Payment criterion – Children’s asthma referrals’ are listed under the ‘Quality Payment Criteria’ heading.

The PharmOutcomes services allows contractors to record patient details who have consented to be referred to their GP practice. When this data is saved on PharmOutcomes, a referral will automatically be sent to the patient’s GP practice (if an NHSmail email address is held for that GP practice on PharmOutcomes).

If a contractor has not used PharmOutcomes before, log in details can be obtained by sending a message to the PharmOutcomes helpdesk. Contractors will need to provide details of the pharmacy, contact information and an email address to issue the login details to. 

Categories: National News

Quality Payments – Asthma referrals (November 2018)

PSNC News - 19 November 2018 - 3:18pm

This PSNC Briefing provides contractors with updated guidance for the February 2019 review point on meeting the ‘referrals for asthma review’ quality criterion of the Quality Payments Scheme.

PSNC Briefing 060/18: Quality Payments – Asthma referrals

If you have any queries on this PSNC Briefing or you require more information, please contact the PSNC Services Team.

To browse other PSNC briefings on services and commissioning click here.

View Article…

Categories: National News

October concession increase for Risperidone 2mg tablets

PSNC News - 16 November 2018 - 3:00pm

Following further representations from PSNC, there will be an increase to the October 2018 price concession for Risperidone 2mg tablets.

The price concession is now set at £20.00 for a pack of 60 tablets. This revised price will be automatically applied to any prescriptions for Risperidone 2mg tablets submitted in October prescription bundles.

Originally imposed at a price of £1.80 by the Department of Health and Social Care (DHSC), PSNC requested a review of the concessionary price on behalf of community pharmacy contractors.

This concession has been put in place for October 2018 only and announcements about any November concessions will be made in due course.

Please do continue to report supply issues using PSNC’s generic shortages form which can be found here.

 

Categories: National News

Drug Tariff Watch: December 2018 changes

PSNC News - 16 November 2018 - 9:00am

The Preface lists additions, deletions and alterations to the Drug Tariff. Below is a quick summary of the changes due to take place from 1st December 2018.

Part VIIIA additions

Category A

  • Tenofovir 245mg tablets (30)

Category C:

  • Co-trimoxazole 80mg/400mg/5ml solution for infusion ampoules (10) – Aspen Pharma Trading Ltd
  • Dexamethasone 8mg tablets (30) – Teva UK Ltd
  • Dexibuprofen 300mg tablets (60) – Seractil
  • Fondaparinux sodium 1.5mg/0.3ml solution for injection pre-filled syringes (10) – Arixtra
  • Fondaparinux sodium 10mg/0.8ml solution for injection prefilled syringes (10) – Arixtra
  • Fondaparinux sodium 2.5mg/0.5ml solution for injection pre-filled syringes (10) – Arixtra
  • Fondaparinux sodium 5mg/0.4ml solution for injection prefilled syringes (10) – Arixtra
  • Fondaparinux sodium 7.5mg/0.6ml solution for injection pre-filled syringes (10) – Arixtra
  • Gentamicin 20mg/2ml solution for injection ampoules (5) – Wockhardt UK Ltd
  • Gentamicin 5mg/1ml solution for injection ampoules (5) – Gentamicin Intrathecal
  • Glycopyrronium bromide powder for solution for iontophoresis (3g) – AMCo
  • Heparin sodium 5,000units/1ml solution for injection ampoules (10) – Wockhardt UK Ltd
  • Lidocaine 200mg/20ml (1%) solution for injection vials (10) – Hameln Pharmaceuticals Ltd
  • Lidocaine 400mg/20ml (2%) solution for injection vials (10) – Hameln Pharmaceuticals Ltd
  • Liquid paraffin liquid (150ml) – Bell,Sons & Co (Druggists) Ltd
  • Liquid paraffin liquid (2000ml) – J M Loveridge Ltd
  • Liquid paraffin liquid (5000ml) – J M Loveridge Ltd
  • Metronidazole 500mg/100ml infusion 100ml bags (20) – AAH Pharmaceuticals Ltd
  • Morphine sulfate 5mg/5ml solution for injection ampoules (10) – Torbay Pharmaceuticals
  • Octreotide 1mg/5ml solution for injection vials n (1) – Pfizer Ltd
  • Octreotide 50micrograms/1ml solution for injection ampoules (5) – Sandostatin
  • Paracetamol 1g/100ml solution for infusion vials (10) – Accord Healthcare Ltd
  • Phenobarbital 60mg/1ml solution for injection ampoules (10) – Martindale Pharmaceuticals Ltd
  • Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 250ml bottles (10) – AAH Pharmaceuticals Ltd
  • Sodium chloride 30% solution for infusion 100ml vials (10) – Torbay Pharmaceuticals
  • Sodium chloride 30% solution for infusion 50ml vials (10) – Torbay Pharmaceuticals
  • Sodium valproate 300mg/3ml solution for injection ampoules (5) – Episenta
  • Sodium valproate 400mg/4ml solution for injection ampoules (5) – Wockhardt UK Ltd
  • Tenofovir 123mg tablets (30) – Viread
  • Tenofovir 163mg tablets (30) – Viread
  • Tenofovir 204mg tablets (30) – Viread
  • Tobramycin 240mg/6ml solution for injection vials n (1) – Pfizer Ltd
  • Tobramycin 80mg/2ml solution for injection vials n (1) – Nebcin
  • Tobramycin 80mg/2ml solution for injection vials (5) – Pfizer Ltd
  • Tranexamic acid 500mg/5ml solution for injection ampoules (10) – Cyklokapron
  • Triamcinolone hexacetonide 20mg/1ml suspension for injection ampoules (10) – Intrapharm Laboratories Ltd
  • Vancomycin 1g powder for solution for infusion vials (10) – Flynn Pharma Ltd
  • Vancomycin 500mg powder for solution for infusion vials (10) – Flynn Pharma Ltd

Part VIIIA amendments

  • Chloramphenicol 5% ear drops n (10ml) – Martindale Pharmaceuticals Ltd is changing to Category A
  • Clonazepam 500micrograms/5ml oral solution sugar free (150ml) – Rosemont Pharmaceuticals Ltd is changing to Category A
  • Diclofenac sodium 100mg modified-release tablets (28) – Volsaid Retard 100 is changing to Fenactol Retard
  • Diclofenac sodium 75mg modified-release tablets (56) – Volsaid Retard 75 is changing to Fenactol SR
  • Morphine sulfate 10mg/1ml solution for injection ampoules (10) – Wockhardt UK Ltd is changing to Category A
  • Ranitidine 150mg/5ml oral solution sugar free (150ml) – Creo Pharma Ltd is changing to Category A
  • Tobramycin 300mg/5ml nebuliser liquid ampoules (56(4 x n14)) – Tobi is changing to Tymbrineb
  • Ursodeoxycholic acid 300mg tablets (60) – Wockhardt UK Ltd is changing to Category A

Part VIIIA deletions

  • Inositol nicotinate 500mg tablets (100) – Hexopal
  • Inositol nicotinate 750mg tablets (112) – Hexopal Forte

Part IX deletions

It is important to take careful note of removals from Part IX because if you dispense a deleted product, prescriptions will be returned as disallowed.

Product Size, type, product code Snap dressing kit – Gauze All sizes Reusable Pens – AllStar All types and sizes Vacuum Pumps – Owen Mumford Ltd – Rapport Premier SM2200 Leg Bags – L.In.C Medical Systems – LINC-Flo sterile leg bag with lever tap, adjustable inlet tube 350ml bag (LM350AD-L) Belts – AMI Medical Ltd – Suportx Ostomy/Hernia Support Belt All except 15cm depth Colostomy bags – ConvaTec Ltd – Colodress Plus (Stomahesive Wafer) Closed Pouches Opaque and clear starter holes Colostomy bags – ConvaTec Ltd – Esteem Closed Pouches with Integral filter All types and sizes Colostomy bags – ConvaTec Ltd – Esteem+ Closed Pouches with Integral filter X Small – opaque All sizes Ileostomy bags – ConvaTec Ltd – Esteem One-Piece Convex Drainable Pouch with InvisiClose Outlet All types and sizes Pressure plates/shields – Salts Healthcare – Convex Plate for Light White Bag All sizes Pressure plates/shields – Salts Healthcare – Plastic Retaining Shield Single 833008 Two piece ostomy systems – ConvaTec Ltd – Esteem Synergy ileostomy bag S1007F, S1021F, S1212F, S1221F, S1222F and S1231F Two piece ostomy systems – Oakmed Ltd – Option Connect 2 colostomy bag with filter, Clear JH520 Two piece ostomy systems – Oakmed Ltd – Option Connect 2 ileostomy bag with filter, Clear JH220 and JH120

Want to learn more about recent Dispensing & Supply news? Read our monthly updates here.

Categories: National News

Quality Payments: NSAID audit now available

PSNC News - 16 November 2018 - 8:30am

Specialist Pharmacy Service has published the non-steroidal anti-inflammatory drug (NSAID) audit, which community pharmacy contractors will need to complete if they intend to claim for the NSAID quality criterion at the February review point of the Quality Payments Scheme.

Contractors will need to have completed the audit, have notified a patient’s GP where professional concerns are identified, share their anonymised data with NHS England (by submitting this to the NHS Business Services Authority (NHS BSA) who are collecting this information on behalf of NHS England) and have incorporated the learning of the audit into future practice by the review point (15th February 2019) to meet the NSAID quality criterion.

Data must be collected for two weeks with a minimum of ten patients participating in the audit. All patients aged 65 years or over who collect a prescription for any oral NSAID or cyclo-oxygenase-2 (COX2) selective inhibitor (this does not include patients prescribed aspirin) should be included in the audit. In cases where there is difficulty in finding ten patients to participate, the audit should be extended to four weeks after which contractors can submit the data with the number of patients they have if less than ten.

Contractors can choose to enter the data directly onto a web-based platform or use the paper form (a standalone form is available at psnc.org.uk/qpaudit) to collect the data and then transfer the data onto a web-based platform to submit their results to NHS BSA. Two web-based systems are available for the audit; PharmOutcomes* or the NHS BSA Snap Survey.

Having reviewed both systems, PharmOutcomes has the following advantages over the NHS BSA Snap Survey:

  • PharmOutcomes can send an automatic referral letter to a patient’s GP practice (if the NHS BSA Snap Survey is used, contractors will need to manually send this referral letter (a template letter is available at psnc.org.uk/qpaudit);
  • A permanent patient record will be stored on PharmOutcomes; and
  • Contractors will not be required to submit their data once they have entered all their audit data onto PharmOutcomes, the system will automatically do this for contractors (if using the NHS BSA Snap Survey, contractors will need to remember to press the ‘Submit’ button once they have completed all their data entry for this to be submitted to NHS BSA. Failure to submit the data will mean the contractor does not meet the NSAID quality criterion).

*The NSAID audit on PharmOutcomes is freely available to all contractors; PSNC has agreed to use their licence to provide access.

FAQs

Q. When do I need to complete the audit?
Contractors can pick a two-week period between November 2018 and 15th February 2019 to complete the audit; however, contractors are encouraged to not leave completion of the audit until February 2019 in case the data collection period needs to be extended to four weeks if contractors have difficulty in finding ten patients to participate.

Q. Will both of the web-based systems calculate my audit results?
Yes. Both of the web-based systems will calculate a contractor’s results. If PharmOutcomes is used, contractors will be able to access the results in the ‘Reports’ section and can print this off as evidence of meeting the NSAID quality criterion. If the NHS BSA Snap Survey is used and the contractor enters an email address when submitting their results, the contractor will be emailed the results of their audit; this email should be retained as evidence of having met the NSAID quality criterion.

Contractors will, however, need to record how they have incorporated the learning of the audit into future practice elsewhere, as this information cannot be recorded on either of the web-based platforms.

Q. If I have not used PharmOutcomes before, how do I obtain log in details?
If a contractor has not used PharmOutcomes before, log in details can be obtained by sending a message to the PharmOutcomes helpdesk. Contractors will need to provide details of the pharmacy, contact information and an email address to issue the login details to.

Q. Where do I access the NSAID audit on PharmOutcomes?
When you log into PharmOutcomes select ‘Services’; you should see ‘NSAID GI Safety Audit 2018/19’ under the ‘National Audits’ heading.

If you have mislaid your PharmOutcomes login details, visit the Help page.

Categories: National News

Workforce concerns raised in advance of NHS long-term plan

PSNC News - 15 November 2018 - 2:54pm

A report on the NHS workforce published today warns that staff shortages could triple in a decade.

Analysis by the Health Foundation, the King’s Fund and the Nuffield Trust – presented in The health care workforce in England: Make or break? – suggests that the health service could be short of more than 350,000 staff by 2030.

The NHS is struggling to recruit and retain the staff needed to meet rising demand and, if this continues at the same rate, the report argues that it could lead to growing waiting lists and a deterioration in the quality of care provided.

The think tanks propose five key tests, which they say the NHS long-term plan will need to pass:

  1. address workforce shortages in the short term;
  2. address workforce shortages in the long term;
  3. support new ways of working;
  4. address race and gender inequalities in pay and progression; and
  5. strengthen workforce and service planning at all levels of the system.

Under test 3, the report advises that existing healthcare staff should be “contributing at the optimum level of their skill set”, suggesting that “pharmacists can take on medication reviews and some elements of long-term condition management”.

Alastair Buxton, PSNC Director of NHS Services, said:

“We agree that HM Government and NHS leaders need to address the mounting challenges facing the NHS workforce, however the network of over 11,600 community pharmacies are ideally placed to assist. As pressure on the NHS workforce increases, it is more important than ever that we make best use of community pharmacies. There is much more that they could do to help keep people healthy and out of hospitals, in particular by caring for people with long-term conditions, being the first port of call for healthcare advice and acting as health and wellbeing hubs.”

Categories: National News

MHRA Drug Safety Update – November 2018

PSNC News - 14 November 2018 - 2:46pm

Date issued: 14th November 2018

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 4, November 2018) has been published and includes articles on:

  • Hydrochlorthiazide: risk of non-melanoma skin cancer, particularly in long-term use.
  • Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high risk patients.
  • Support Yellow Card: help improve the safety of medicines in pregnancy and breastfeeding, and in babies and children.

To sdee the latest MHRA Drug Safety Update in full, visit the GOV.uk website.

 

Categories: National News

CPPE Corner: Mary Seacole Leadership Programme for community pharmacy

PSNC News - 14 November 2018 - 2:42pm

Community pharmacists and pharmacy technicians can develop their leadership and management skills with an interactive programme from the Centre for Pharmacy Postgraduate Education (CPPE). We spoke to Lesley Grimes, CPPE lead pharmacist, learning development, to find out more.

Following the success of the first cohorts of the Mary Seacole Leadership Programme for community pharmacy in 2017, we have collaborated with the NHS Leadership Academy to offer the Mary Seacole Leadership programme to pharmacists and pharmacy technicians working in community pharmacy.

Places on the programme are fully funded by the Pharmacy Integration Fund (PhIF). To apply, you need to register for an account with the NHS Leadership Academy and then complete the online registration form.

While some of the cohorts have already been filled, there are still plenty of spaces available in a number of cohorts across the country including:

  • Reading
  • London
  • Liverpool
  • Wimborne (Dorset)
  • Coventry
  • Leeds
  • Nottingham

We have also recently opened up a new cohort in Birmingham that will start on 13th March 2019. The next two cohorts are in Liverpool and Wimborne (Dorset) and the deadlines for applications are on 27th November 2018 and 29th November 2018 respectively.

The Mary Seacole Leadership programme is designed to help you feel more confident in your leadership skills by helping you to identify your strengths and areas for improvement and finding the right style to suit you. The programme is comprised of a six-month interactive online course with support from an online tutor and three compulsory one-day workshops.

On the dedicated Mary Seacole page on the CPPE website, you can find a collection of quotes and video testimonials from participants of the programme, who share their thoughts and experiences.

Categories: National News

Medical device alert and recall – potential breach in sterile barrier packaging of some products manufactured by ConvaTec Limited

PSNC News - 14 November 2018 - 12:40pm

ConvaTec has voluntarily initiated a recall of specific product codes of Suction Catheters, Gastroenteral Tubes, Intermittent Urology Catheters and sterile Urine Drainage Bags due to the potential breach in sterile barrier packaging. Only the identified product codes and affected lots within this notice may have a potential breach in the sterile barrier packaging.

Action
  • Refer to the manufacturer’s Field Safety Notice FSN for a list of affected product codes and affected lots.
  • Stop using and quarantine affected devices as directed in the manufacturer’s FSN.
  • Complete the ‘Recall Response Form for END USERS’ in the FSN and return to convatecproductrecall@stericycle.com to arrange return of affected device(s).
  • Report any incidents or complaints involving this product to unomedical-uk.customerservice@convatec.com.

 

Date issued: 14th November 2018

MDA number: MDA/2018/034

Affected products: Full list

Manufacturer contacts

ConvaTec Limited Tel: 01244 832206

Recall centre:  convatecproductrecall@stericycle.com

Email: unomedical-uk.customerservice@convatec.com

 

To view the alert please visit the GOV.UK website.

Categories: National News

Christmas opening hours

PSNC News - 13 November 2018 - 5:08pm

Community pharmacy contractors do not have to open on days which are specifically mentioned in the Regulations (namely Christmas Day, Good Friday and Easter Sunday) or a day which has been specifically designated as a ‘bank holiday’, unless directed to open by their local NHS England team.

In December, contractors in England will not be required to open on the following days (unless otherwise directed by their local NHS England team):

  • Christmas Day (25th December 2018)
  • Boxing Day (26th December 2018)

Contractors will also not be required to open on New Year’s Day which falls on Tuesday 1st January 2019.

PSNC’s annual opening hours factsheet provides contractors with a quick reference guide on which public and bank holidays pharmacies can close without giving notice. This is available to download here.

Categories: National News

Mitomycin-C 10mg Powder for Solution for Injection (Kyowa): Company led drug alert

PSNC News - 12 November 2018 - 4:17pm

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company led drug recall, to be actioned, for certain batches of: Mitomycin-C Kyowa 10mg Powder for Solution for Injection.

Date issued: 12th November 2018

CLDA number: (18) A/09

MDR number: MDR 06-11/18

Batch number: 6058517

The above batch is being recalled because an out of specification result for sub visible particles was recorded at the 39 month time point.

Company contact for stock enquiries:

Martin Smith

Tel: 01896 664030

Email: Martin.Smith@kyowakirin.com

Company contact for medical information enquiries:

Gary Speake

Tel: 01896 664029

Email: Medicalaffairs@kyowakirin.com or Gary.speake@kyowakirin.com

 

To view the alert please visit the GOV.UK website.

 

 

Categories: National News

FMD webinar now on-demand

PSNC News - 8 November 2018 - 1:15pm

Community pharmacy contractors can now access an online recording of PSNC’s recent webinar about the Falsified Medicines Directive (FMD).

More than 1,000 people registered for yesterday’s webinar hosted by Alastair Buxton, PSNC’s Director of NHS Services. Alastair used the event to explain how the introduction of FMD will affect the day-to-day working of community pharmacy teams and what they need to do to prepare.

Some of the feedback we have received so far:

“I enjoyed the FMD Webinar. The length of time allocated was just right.” – Pharmacist

“Excellent way of passing the news and educating pharmacists in the UK, thank you very much for your hard work.” – Pharmacy Manager

“Very well presented. Thank you.” – Director/Owner

During the webinar, Alastair described the new processes that FMD will introduce and outlined the guidance and resources developed by the UK FMD Working Group for Community Pharmacy. He also answered a number of viewers’ questions.

With the implementation of FMD now less than three months away (February 2019), this webinar provides contractors and their teams with key actions for them to undertake in advance of that date.

Click here to view an on-demand version of the webinar.*

You can also click here to view the slide pack used in the webinar.

*Please note, to watch the recording, you will need to register (or input the email address you registered with previously).

Categories: National News

PSNC October Meeting: summary for contractors now available

PSNC News - 7 November 2018 - 5:07pm

PSNC’s October meeting was held on the 9th and 10th of the month in Swindon, and key agenda items included:

Download the summary of the October PSNC meeting here.

Further details regarding PSNC’s ongoing work will be shared on the website as soon as possible.

Categories: National News

Secretary of State advances the prevention agenda

PSNC News - 6 November 2018 - 5:50pm

The Secretary of State for Health and Social Care, Matt Hancock MP, has released a policy paper setting out the Government’s plan to put prevention at the centre of healthcare.

The paper, Prevention is better than cure, sets out plans to diagnose cancer earlier, tackle obesity and use technology to predict illness, in a drive to increase life expectancy by five years. It also stresses that individuals need to take extra responsibility for their wellbeing by adopting healthier lifestyles.

Mr Hancock announced that a Green Paper on Prevention will be published in the first half of 2019. This sits alongside his Department’s wider work in creating a long-term plan for the NHS.

PSNC’s response to the long-term plan consultation called for further commissioning of services to enable community pharmacies to do more to help people to stay healthy and so we welcome a reference to this in the policy paper:

‘The Government wants to encourage more people to make the most of their local pharmacy, and for local pharmacies to play a stronger role in helping people stay healthy.  There are almost 10,000 community pharmacies registered as Healthy Living Pharmacies in England. They deliver a wide range of lifestyle and health interventions, and promote wellbeing and self-care services.’

After Mr Hancock outlined his plans during a session at the House of Commons, Bim Afolami, MP for Hitchin and Harpenden, asked what his views are for community pharmacy as part of the strategy for prevention and Mr Hancock replied that community pharmacies have a “hugely important role to play in keeping people out of hospital and in supporting GP surgeries by doing more”.

Pauline Latham, MP for Mid Derbyshire, followed this up with a suggestion that the Secretary of State visit a community pharmacy in her constituency and Mr Hancock indicated that he would do so as part of a nearby visit due to take place later this month.

PSNC Chief Executive Simon Dukes said:

“We agree with the Secretary of State that we must do more to support preventative healthcare – this should help both people to live longer, healthier lives, and the health service to manage the increasing demands being placed on it. We were pleased to note the acknowledgement in this policy paper that local pharmacies can play a stronger role in helping people to stay well. We very much agree – community pharmacies are ideally placed to help people to stay healthy and avoid visits to hospital – and look forward to working with HM Government to make this shared vision a reality.”

Categories: National News

Update to adrenaline 150 microgram auto-injector validation protocol – urgent action required by pharmacy teams

PSNC News - 6 November 2018 - 3:41pm

A revised interim protocol on dispensing adrenaline 150 microgram auto-injectors has been issued by the Department of  Health and Social Care (DHSC).

Stock levels are now sufficient to ensure that – with immediate effect – every patient that presents a prescription will be able to have access to at least two adrenaline auto-injectors that are either in date or have a formally extended expiry date

Supplies may be constrained until the end of the year due to the backlog of patients requiring new devices.

The existing dispenser and wholesaler prescription validation processes will continue for all adrenaline 150 microgram auto-injector prescriptions (private and NHS).

Steps for pharmacies to take:

1. Read the updated protocol from DHSC, noting in particular:

  • The revised flow chart of questions to ask patients to ascertain those who are in most need of supply;
  • The extension to the usability of some batches of Jext 150 and 300 micrograms, previously advised of EpiPen 300 microgram expiry extension; and

2. Read the updated FAQs prepared by DHSC

3. Implement the protocol with immediate effect

Note this advice is interim and will be reviewed and relaxed whenever possible, but remains in force until further notice.

Please see our dedicated adrenaline resource page for all the latest and previous guidance following the adrenaline 150 microgram auto-injector supply disruption.

 

Categories: National News

Change in the classification of certain glucosamine containing products

PSNC News - 6 November 2018 - 12:37pm

Glucosamine containing products (GCPs), marketed as food supplements, with dosage levels of base glucosamine at 1178mg/day or higher can no longer be sold or supplied by pharmacy teams as they are now considered unauthorised medicines. It is important to note that under Regulation 47 of the Human Medicines Regulations 2012 it is an offence to sell or supply an unauthorised medicinal product (unless an exception applies). GCPs with a daily dose of base glucosamine at, or exceeding 1178mg/day are now regarded as medicines. In practice, this mainly affects food supplements which are marketed with daily dosage levels of 1500mg glucosamine sulphate or glucosamine hydrochloride1. GCPs that already have a valid marketing authorisation (for example, Dolenio) remain unaffected.

The reclassification follows a 2016 Court of Appeal Judgement, after which the Medicines and Healthcare products Regulatory Agency (MHRA) conducted a review to understand how and why glucosamine is used by consumers. The review found that GCPs are mainly used for medicinal purposes to treat symptoms of osteoarthritis of the knee and for general joint health. The evidence of pharmacological effect was then used to determine the dosage levels of base glucosamine (1178mg/day) at which GCPs cannot be sold without a valid marketing authorisation.

Information for Pharmacy Teams

MHRA have advised that affected GCPs should be removed from counter and dispensary shelves to avoid the inadvertent sale or supply of unauthorised medicinal products. Any prescriptions received for GCPs with a daily dose of base glucosamine at 1178mg which cannot be met by a licenced product should be referred back to the prescriber.

GCPs that can no longer be dispensed or sold over-the-counter as food supplements:

  • GCPs with a daily dose of base glucosamine at 1178mg/day or higher

GCPs that can legally be dispensed or sold over-the-counter as food supplements:

  • GCPs with a daily dose of base glucosamine less than 1178mg

 

If you require further information on this change, please contact borderline_medicine@mhra.gov.uk

For the MHRA news story go to the MHRA website here

 

1 1500mg glucosamine sulphate or glucosamine hydrochloride contain base glucosamine levels of 1178mg and 1246mg respectively.

Glucosamine sulphate is available in two salt forms; a sodium chloride and potassium chloride salt form. This means that, in practice, more than 1500mg of either salt form is added to achieve 1500mg of glucosamine sulphate and, therefore, a base glucosamine level of 1178mg.

In licensed medicines 1884.60mg of the sodium salt is added to achieve 1500mg/day of glucosamine sulphate, providing 1178mg of base glucosamine.

Glucosamine sulphate [2NaCl] contains 79.6% glucosamine sulphate and 62.5% base glucosamine.
Glucosamine sulphate [2KCl] contains 75.4% glucosamine sulphate and 59.2% base glucosamine.

 

Categories: National News

Quality Payments: DoS Profile Updater now available

PSNC News - 5 November 2018 - 3:53pm

The Directory of Services (DoS) Profile Updater, which community pharmacy contractors will need to use to meet the DoS quality criterion of the second Quality Payments Scheme 2018/19, is now available.

Contractors who plan to claim for the DoS quality criterion at the February 2019 review point are required to edit or confirm the information about their pharmacy is correct on the DoS Profile Updater between 10am on 5th November and 11:59pm on 15th February 2019 to meet the DoS quality criterion. This process is the same for ‘bricks and mortar’ pharmacies and distance selling pharmacies.

Contractors are reminded that they are required to ensure their NHS 111 DoS entry is up-to-date, which includes bank holiday opening hours. The bank holiday opening hours that contractors need to add to meet the DoS quality criterion are as follows:

Friday 19th April 2019 Good Friday Sunday 21st April 2019 Easter Sunday* Monday 22nd April 2019 Easter Monday Monday 6th May 2019 Early May bank holiday Monday 27th May 2019 Spring bank holiday

Guidance on how to edit or confirm the information about a pharmacy is correct is available on the DoS Profile Updater website (this can also be accessed by clicking on ‘Help’ at the bottom of the screen on the DoS profile updater homepage). Contractors are strongly advised to read the guidance to ensure they fully understand how to meet the quality criterion.

Once the details on the DoS Profile Updater have been edited or confirmed and then submitted, the contractor will receive an email to confirm this. This email should be retained as evidence of meeting the DoS quality criterion.

Further information on the DoS quality criterion is available on psnc.org.uk/QPDoS

*Although Easter Sunday is not officially a bank holiday, NHS England has requested that contractors add their opening hours for this date to assist local NHS England teams and DoS leads so they know which pharmacies will be open over the Easter weekend.

Frequently asked questions

Q. I updated my pharmacy’s details on the DoS Profile Updater in October 2018, therefore do I meet the quality criterion?
No. To meet the DoS quality criterion, contractors must check the pharmacy details and submit this information on the DoS Profile Updater between 10am on 5th November 2018 and 11.59pm on 15th February 2019.

Q. There are other bank holiday dates listed (before Easter and after the Spring bank holiday), do I need to add my opening hours for these bank holidays?
No. To meet the DoS quality criterion, contractors must add their opening hours for the bank holidays listed above. Completion of the other bank holidays is not mandatory to meet the quality criterion but if contractors know this information and wish to add it then they may do so.

Q. What do I do if I don’t receive an email confirming that I have submitted information on the DoS Profile Updater?
The email should be received instantaneously after submitting the information on the DoS Profile Updater; however, please allow up to two hours for the email to be delivered. To help ensure contractors receive their confirmation emails, contractors are advised to add noreply@dos-profile.service.nhs.uk to their safe senders list before they update their profile. Alternatively, contractors will need to check their junk email folder in case the email has been inappropriately filed. If the emails are not received, please email exeter.helpdesk@nhs.net to confirm that the submission has been received.

Q. What do I do if I am experiencing technical difficulties accessing the DoS Profile Updater?
If contractors have any technical difficulties accessing the DoS Profile Updater, they can email the NHS Digital helpdesk (exeter.helpdesk@nhs.net) or call them on 0300 303 4034.

Categories: National News
Syndicate content